The new expanded User Registry for the iLA Membrane Ventilator® has officially been launched. The Registry is an ongoing, worldwide collection of clinical data in which any hospital that uses the iLA Membrane Ventilator® can participate. In contrast to randomized studies with fixed study protocols, the iLA Registry enables an accurate representation of daily clinical reality, since all patients are included. Every participating hospital will receive an objective analysis of their own data in regular intervals. The worldwide scope of the Registry promotes the exchange of experiences between large and small hospitals, both domestically and internationally.
The redesigned iLA Registry was presented in Bremen, Germany, at one of the most important German intensive-care meetings, the 20th Symposium for Intensive-Care Medicine and Nursing. Clinical data from users for users will now be systematically collected under the guidance of Dr. Rolf Dembinski (Aachen University Hospital, Germany) and Prof. Dr. Thomas Bein (Regensburg University Hospital, Germany). The chairs of the iLA Study Group see this as a great opportunity to obtain a clear picture of the clinical status of the procedure and to more accurately describe its effect on clinically relevant outcome parameters such as time on ventilation, length of stay in the ICU and mortality.
The iLA Registry was introduced in 2007 by Novalung’s Clinical Support group and currently includes over 400 patients. Preliminary analyses in 2008 and 2009 already pointed to clear, interesting trends in the use of the iLA Membrane Ventilator®. While it initially consisted primarily of patients with severe lung failure (e.g., ARDS) in an artificial coma, nearly two-thirds of the patients registered in 2009 suffered from an acute exacerbation of chronic lung failure (such as COPD) requiring in-hospital treatment. These patients in particular might benefit from treatment with the iLA Membrane Ventilator®, since it provides the possibility of avoiding mechanical ventilation entirely.
Novalung‘s Mission is the creation of new solutions for lung failure using innovative artificial lungs that breathe outside the patient’s body. Its pioneering task is to work with leading physicians globally to create new treatments that can replace the damaging procedure of mechanical ventilation.
The redesigned iLA Registry was presented in Bremen, Germany, at one of the most important German intensive-care meetings, the 20th Symposium for Intensive-Care Medicine and Nursing. Clinical data from users for users will now be systematically collected under the guidance of Dr. Rolf Dembinski (Aachen University Hospital, Germany) and Prof. Dr. Thomas Bein (Regensburg University Hospital, Germany). The chairs of the iLA Study Group see this as a great opportunity to obtain a clear picture of the clinical status of the procedure and to more accurately describe its effect on clinically relevant outcome parameters such as time on ventilation, length of stay in the ICU and mortality.
The iLA Registry was introduced in 2007 by Novalung’s Clinical Support group and currently includes over 400 patients. Preliminary analyses in 2008 and 2009 already pointed to clear, interesting trends in the use of the iLA Membrane Ventilator®. While it initially consisted primarily of patients with severe lung failure (e.g., ARDS) in an artificial coma, nearly two-thirds of the patients registered in 2009 suffered from an acute exacerbation of chronic lung failure (such as COPD) requiring in-hospital treatment. These patients in particular might benefit from treatment with the iLA Membrane Ventilator®, since it provides the possibility of avoiding mechanical ventilation entirely.
Novalung‘s Mission is the creation of new solutions for lung failure using innovative artificial lungs that breathe outside the patient’s body. Its pioneering task is to work with leading physicians globally to create new treatments that can replace the damaging procedure of mechanical ventilation.
